Royalty Pharma (RPRX) Receivables Refunds (2019 - 2025)
Historic Receivables Refunds for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $28.9 million.
- Royalty Pharma's Receivables Refunds rose 1606.36% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 1606.36%. This contributed to the annual value of $27.0 million for FY2024, which is 2031.24% up from last year.
- Royalty Pharma's Receivables Refunds amounted to $28.9 million in Q3 2025, which was up 1606.36% from $27.7 million recorded in Q2 2025.
- Royalty Pharma's 5-year Receivables Refunds high stood at $28.9 million for Q3 2025, and its period low was $6.5 million during Q1 2021.
- In the last 5 years, Royalty Pharma's Receivables Refunds had a median value of $21.6 million in 2023 and averaged $20.0 million.
- Per our database at Business Quant, Royalty Pharma's Receivables Refunds soared by 23981.57% in 2021 and then soared by 64.75% in 2024.
- Quarter analysis of 5 years shows Royalty Pharma's Receivables Refunds stood at $15.0 million in 2021, then skyrocketed by 31.58% to $19.8 million in 2022, then rose by 13.35% to $22.4 million in 2023, then grew by 20.31% to $27.0 million in 2024, then grew by 7.22% to $28.9 million in 2025.
- Its Receivables Refunds stands at $28.9 million for Q3 2025, versus $27.7 million for Q2 2025 and $23.8 million for Q1 2025.